Bausch Health · conference-presentation
Bausch Health Companies | Results Presentation Deck | 90 slides
90 pages · 4 arc beats · 2 loops
Bausch Health Companies | Results Presentation Deck | 90 slides
Bausch Health · 2021-08 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
151015202530354045505560657075808590
Deck intelligence map
4 coverage by narrative range · generated from this deck JSON
Narrative range 90 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Attention 5 slides 100% 5/5 slides 100% 5/5 slides · 23 hits — 0/5 slides
20% 1/5 slides 20% 1/5 slides 100% 5/5 slides — 0/5 slides
Need 9 slides 100% 9/9 slides 100% 9/9 slides · 30 hits — 0/9 slides
33.3% 3/9 slides · 4 hits 11.1% 1/9 slides 100% 9/9 slides 100% 9/9 slides Satisfaction 12 slides 100% 12/12 slides 100% 12/12 slides · 72 hits — 0/12 slides
25% 3/12 slides · 4 hits 8.3% 1/12 slides 100% 12/12 slides 100% 12/12 slides Action 64 slides 100% 64/64 slides 100% 64/64 slides · 256 hits — 0/64 slides
29.7% 19/64 slides 3.1% 2/64 slides 100% 64/64 slides — 0/64 slides
Slide inventory
90 every slide · same image gating as the playbook
02
Includes specific references to COVID-19 impacts, Solta Medical IPO, and eye health business spin-off.other
Open slide detailBeat · Attention
05
Includes a donut chart showing revenue breakdown by business unit.summarize
Open slide detailBeat · Attention
06
The table breaks down revenue by segment and sub-segment, showing reported and organic growth percentages.analyze_data
07
Includes detailed footnotes regarding non-GAAP adjustments, constant currency calculations, and specific exclusions.analyze_data
08
Includes extensive footnotes detailing adjustments and exclusions.analyze_data
09
Includes footnotes detailing debt adjustments and divestiture impacts.analyze_data
10
The table uses a blue box to visually emphasize the 'no maturities' period from 2021-2023.analyze_data
12
The slide uses color-coding to highlight the most recent guidance (August 2021) in blue text.analyze_data
13
The slide uses two parallel waterfall charts to illustrate the bridge between May and August guidance for two key financial metrics.show_valuation_bridge
15
The slide uses a pie chart for revenue composition and bulleted lists for segment-specific performance highlights.analyze_data
16
The slide uses a mix of bar charts and line charts to illustrate recovery trajectories for different business segments.summarize
17
The chart uses a visual 'Recovery in Progress' arrow to highlight the rebound from COVID-19 impacts.analyze_data
18
The slide uses trend lines to highlight recovery and strong performance across three distinct product lines.analyze_data
19
Includes a bar chart for organic growth, a donut chart for regional revenue breakdown, and callouts for top products by region overlaid on a world map.analyze_data
21
Includes leadership headshots and disclaimer.summarize
23
The slide uses two bar charts to demonstrate financial performance and operating leverage.analyze_data
25
Includes company overview and product logos on the right side.introduce_nominees
26
The slide uses a process flow diagram to show how operational improvements (EBITDA growth, working capital, deleveraging) feed into specific divestiture and IPOplan_implementation
30
The slide uses a flow diagram to show how business lines were re-categorized into new segments.present_framework
Open slide detailBeat · Action
31
The slide details the financial impact of segment restructuring, showing reported vs. restated figures.show_valuation_bridge
Open slide detailBeat · Action
32
The slide uses specific financial growth targets to communicate future performance expectations.summarize
Open slide detailBeat · Action
34
The slide uses a timeline framework to map four distinct drug development programs against a 2019-2027 calendar.plan_implementation
Open slide detailBeat · Action
35
The table tracks financial performance changes for products that have experienced or are anticipating LOE.analyze_data
Open slide detailBeat · Action
36
LOE = Loss of Exclusivity. Data shows significant revenue and profit declines across all business units due to patent expirations.analyze_data
Open slide detailBeat · Action
37
The table tracks financial impact of patent expirations across Bausch & Lomb, Int'l Rx, Salix, Ortho Dermatologics, and Diversified Products.analyze_data
Open slide detailBeat · Action
38
The table compares inventory levels between Q1 and Q2 for two consecutive years.analyze_data
Open slide detailBeat · Action
39
The table tracks inventory efficiency across different business segments.analyze_data
Open slide detailBeat · Action
40
The slide includes a specific callout for organic revenue growth and a disclaimer regarding corporate cost allocation.analyze_data
Open slide detailBeat · Action
41
The slide includes a specific callout for +28% organic revenue growth.analyze_data
Open slide detailBeat · Action
42
Includes non-GAAP metrics like Constant Currency and Organic Change.analyze_data
Open slide detailBeat · Action
43
Includes non-GAAP metrics and segment-specific performance data.analyze_data
Open slide detailBeat · Action
44
The table includes reported, constant currency, and organic change metrics.analyze_data
Open slide detailBeat · Action
45
Includes detailed footnotes regarding non-GAAP adjustments and currency impacts.analyze_data
Open slide detailBeat · Action
46
Includes footnotes regarding non-GAAP metrics and segment reporting.analyze_data
Open slide detailBeat · Action
47
The slide highlights a 12% organic growth for the Salix segment.analyze_data
Open slide detailBeat · Action
48
The slide highlights a 10% organic revenue growth for the International Rx segment.analyze_data
Open slide detailBeat · Action
49
The slide includes a specific callout for Global Solta's organic revenue growth.analyze_data
Open slide detailBeat · Action
50
Includes non-GAAP metrics like EBITA and organic change.analyze_data
Open slide detailBeat · Action
51
Includes footnotes regarding non-GAAP information and constant currency calculations.analyze_data
Open slide detailBeat · Action
52
Includes footnotes regarding non-GAAP information and constant currency calculations.analyze_data
Open slide detailBeat · Action
53
The table tracks revenue in millions for 10 products from 2Q20 to 2Q21.analyze_data
Open slide detailBeat · Action
54
The table provides a comparative view of product revenue across five quarters (2Q20 to 2Q21).analyze_data
Open slide detailBeat · Action
55
The table tracks 10 products across 5 quarters, totaling 50 data points.analyze_data
Open slide detailBeat · Action
56
The table tracks revenue in millions for 10 products across 5 quarters (2Q20 to 2Q21).analyze_data
Open slide detailBeat · Action
58
The table lists 10 products with their respective revenue figures for 2Q21, 1Q21, 4Q20, 3Q20, and 2Q20.analyze_data
Open slide detailBeat · Action
59
The table reconciles net loss to adjusted net income (non-GAAP) by detailing specific adjustments like amortization, impairments, and restructuring costs.analyze_data
Open slide detailBeat · Action
60
Includes footnotes regarding non-GAAP adjustments and corporate allocation exclusions.analyze_data
Open slide detailBeat · Action
61
The table provides a breakdown of specific financial line items for Bausch + Lomb, likely for reconciliation or segment reporting purposes.analyze_data
Open slide detailBeat · Action
62
The slide includes two distinct tables: one for revenue and one for segment profit/EBITA.analyze_data
Open slide detailBeat · Action
63
Includes footnotes regarding the definition of Bausch Pharma, estimate status, and inclusion of specific costs in G&A.analyze_data
Open slide detailBeat · Action
64
Contains footnotes regarding non-GAAP adjustments and reporting basis.analyze_data
Open slide detailBeat · Action
65
The table provides a detailed breakdown of financial metrics for the International Rx segment, including non-GAAP profit measures.analyze_data
Open slide detailBeat · Action
66
The table breaks down financial metrics for Ortho Dermatologics and Global Solta, providing a detailed view of segment profitability.analyze_data
Open slide detailBeat · Action
67
Contains footnotes regarding non-GAAP information and segment reporting structure.analyze_data
Open slide detailBeat · Action
68
The slide presents two separate tables for Q2 2021 and Q2 2020, detailing adjustments for items like amortization, impairments, and restructuring costs.analyze_data
Open slide detailBeat · Action
69
The slide contains two distinct tables for 2021 and 2020, detailing various expense adjustments.analyze_data
Open slide detailBeat · Action
70
Contains multiple tables for quarterly and annual financial data.analyze_data
Open slide detailBeat · Action
71
The table reconciles GAAP to non-GAAP figures by adding back acquisition-related costs and adjustments.analyze_data
Open slide detailBeat · Action
72
The table provides a detailed breakdown of various financial adjustments including impairments, restructuring costs, and other non-recurring items.analyze_data
Open slide detailBeat · Action
73
Contains two separate tables: one for annual periods (2017-2020) and one for quarterly periods (2020-2021).analyze_data
Open slide detailBeat · Action
75
The table provides a detailed breakdown of revenue adjustments including exchange rates, divestitures, and discontinuations.analyze_data
Open slide detailBeat · Action
76
The table adjusts reported revenue for changes in exchange rates and divestitures/discontinuations to arrive at organic revenue.analyze_data
Open slide detailBeat · Action
77
The slide presents two side-by-side tables representing different periods for comparison.analyze_data
Open slide detailBeat · Action
78
The table is split into two main sections comparing current periods to prior periods to derive organic growth.analyze_data
Open slide detailBeat · Action
79
The table reconciles reported revenue to organic revenue by adjusting for exchange rates, divestitures, and discontinuations.analyze_data
Open slide detailBeat · Action
80
The slide provides a detailed breakdown of adjustments (exchange rates, divestitures) to arrive at non-GAAP organic revenue figures.analyze_data
Open slide detailBeat · Action
81
The table reconciles GAAP operating cash flow to a non-GAAP adjusted figure by adding back legacy legal settlements, separation costs, and adjusting for Amoun oanalyze_data
Open slide detailBeat · Action
82
The table reconciles Net loss to Adjusted EBITDA by adding back interest, taxes, depreciation, and various non-recurring or non-cash adjustments.analyze_data
Open slide detailBeat · Action
83
The right-hand sidebar acts as a navigation menu for the appendix section.appendix
Open slide detailBeat · Action
84
The right-hand sidebar acts as a navigation menu for the appendix section.appendix
Open slide detailBeat · Action
85
The right-hand sidebar lists the specific non-GAAP measures being defined in the appendix.appendix
Open slide detailBeat · Action
86
The right-hand sidebar lists specific non-GAAP measures being disclosed in the appendix.appendix
Open slide detailBeat · Action
87
The slide serves as a glossary/disclosure page for financial metrics.appendix
Open slide detailBeat · Action
88
The right-hand sidebar acts as a navigation menu for the appendix section.appendix
Open slide detailBeat · Action
89
This slide serves as a glossary/methodology reference for financial reporting.appendix
Open slide detailBeat · Action
90
The slide features a sidebar navigation menu listing various non-GAAP metrics.appendix
Open slide detailBeat · Action